Clinical Trials Logo

Filter by:
NCT ID: NCT05821738 Recruiting - Clinical trials for Core Binding Factor Acute Myeloid Leukemia

Avapritinib in CBF-AML With KIT Mutations

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

AML with t(8; 21)(q22; q22) or inv(16)(p13; q22)/t(16; 16)(p13; q22) is known as CBF-AML. KIT mutations are common in CBF-AML, which have a worse prognosis.This study is aimed to evaluate the efficacy of Avapritinib, an highly specific inhibitor of the KIT gene, in CBF-AML with KIT mutations.

NCT ID: NCT05821452 Not yet recruiting - Chemotherapy Clinical Trials

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Start date: May 25, 2023
Phase: Phase 2
Study type: Interventional

The investigators conducted a phase II, prospective, two-arm clinical study to explore the efficacy of Camrelizumab combined with chemotherapy versus chemoradiotherapy for conversion therapy of potentially resectable advanced esophageal squamous cell carcinoma. This study will provide more evidence for conversion treatment of initially unresectable locally advanced esophageal squamous cell carcinoma and contribute to the development of treatment guidelines for esophageal cancer.

NCT ID: NCT05821400 Recruiting - Clinical trials for Healthy Controls Without Orthostatic Hypotension

Cognitive Changes in Mild Cognitive Impairment

Start date: March 1, 2023
Phase:
Study type: Observational

Background: In recent years, the changes of cognitive function in mild cognitive impairment have attracted attention. Methods/design: We will follow up at 3. The primary outcome will be the measurement of cognitive function using neuropsychological assessment scales such as MOCA, MMSE, etc... Minor variables will be included plasma biomarkers (Aβ, Tau, GFAP, etc.), multimodal brain electrophysiology (P300, VP300, heart rate variability, etc.), and neuroimaging indicators (NODDI).

NCT ID: NCT05821361 Not yet recruiting - Clinical trials for Unrescetable Hepatocellular Carcinoma

HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of HAIC combined with Cadonilimab and bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma

NCT ID: NCT05821192 Recruiting - Clinical trials for Angioimmunoblastic T-cell Lymphoma

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Start date: March 23, 2023
Phase: N/A
Study type: Interventional

A multi-center, prospective clinical study to evaluate the efficacy and safety of R-GDP plus PD-1 monoclonal antibody in the treatment of refractory or relapsed peripheral T cell lymphoma not otherwise specified and Angioimmunoblastic T-cell lymphoma, which has previously shown promising efficacy.

NCT ID: NCT05820906 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Cadonilimab in combination with Regorafenib and Gem-Cis chemotherapy in advanced biliary tract Cancer

NCT ID: NCT05820880 Completed - Hypertension Clinical Trials

Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension

Start date: May 6, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of a fixed-dose combination of perindopril 5 mg /indapamide 1.25 mg / amlodipine 5 mg compared to the free combination of the same components (perindopril 4 mg / indapamide 1.25 mg in a single pill and amlodipine 5 mg pill given separately at the same time) in chinese patients with uncontrolled essential hypertension.

NCT ID: NCT05820607 Recruiting - Clinical trials for Autoimmune Gastritis

Clinical Characteristics, Lifestyle and Multi-omics Analysis in Autoimmune Gastritis

Start date: June 19, 2022
Phase:
Study type: Observational

This research will be conducted nationwide in patients with autoimmune gastritis, focusing on their clinical characteristics, possible risk factors, and multi-omics analysis. Changes in gastrointestinal microbiota, host and microbial metabolism, gene transcription and biomarkers of autoimmune gastritis will be explored to provide evidence for further precise therapy of the disease.

NCT ID: NCT05820503 Completed - Quality of Recovery Clinical Trials

Effect of Nerve Block Under Ultrasound on Postoperative Prognosis in Children

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The goal of this study was to compare the incidence of pain and recovery agitation after single-port laparoscopic inguinal hernia repair in children. The main questions it aims to answer are: - Reduction of postoperative pain by rectus sheath block compared with local anesthesia infiltration and control group - A comparison between rectus sheath block and local anesthesia infiltration and control group on the reduction of agitation during postoperative recovery If there is a comparison group: The researchers will compare the ultrasound-guided rectus sheath group with the local anesthesia infiltration group and the control group to look at postoperative pain indicators and the incidence of waking agitation.

NCT ID: NCT05820165 Recruiting - Image Clinical Trials

Brain Imaging in Cerebral Venous Outflow Disturbance

Start date: March 1, 2023
Phase:
Study type: Observational

Cerebral venous outflow disturbance can lead to cerebral hemodynamic disturbances, altered cerebrospinal fluid dynamics, cerebral venous blood stasis, increased cerebral venous pressure and decreased cerebral perfusion, cerebral white matter sparing-like changes, and widening of retinal vessel diameter. These changes are associated with numerous neurological signs and symptoms. Therefore, understanding the brain structural and functional changes in patients with cerebral venous outflow disturbance is essential to provide specific imaging evaluation indicators and new diagnosis and treatment methods for patients with cerebral venous return disorders.